Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.
Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, Hisada T, Kitano S, Obinata H, Yokobori T, Mori K, Nishiyama M, Tsushima Y, Asao T.
Kaira K, et al. Among authors: asao t.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66. doi: 10.1007/s00259-017-3806-1. Epub 2017 Aug 21.
Eur J Nucl Med Mol Imaging. 2018.
PMID: 28828507